Monoclonal Antibody Therapy for COVID-19
Due to lack of supply, Hackensack Meridian Health is not scheduling additional monoclonal therapy appointments at this time.
Most previously used monoclonal antibody (mAb) treatments are ineffective against COVID-19's omicron variant. As of December 23, 2021, the federal government suspended further shipments of several monoclonal treatments pending further data and guidance from the CDC. Recent studies have shown sotrovimab from GlaxoSmithKline is the only approved monoclonal treatment that is still effective against omicron.
Due to lack of supply of sotrovimab, Hackensack Meridian Health is not scheduling additional monoclonal therapy appointments at this time.
As soon Hackensack Meridian Health receives additional supply, we will begin administering monoclonal therapy and scheduling appointments.